Clinical Development Development In-Vivo Protein 
Drug Discovery World
JUNE 10, 2024
VALANX Biotech has reported successful in vivo results in its lead programme VLX101 for the treatment of a range of autoimmune diseases. Protein drugs hold great promise as therapeutics for a wide range of diseases, however, one of the greatest challenges is their short circulation half-life.
XTalks
OCTOBER 20, 2023
Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. Merck will also make royalty payments on any approved products developed out of the partnership.
pharmaphorum
JULY 5, 2022
The two partners will take an in vivo approach to the problem of so-called sensorineural hearing loss (SNHL) looking at ways to replace sound-detecting hair cells in the inner ear (cochlea) that become damaged in this type of deafness. An estimated 1.57 Astellas is already working on other approaches to treating hearing loss.
Drug Discovery World
MARCH 26, 2024
DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?
The Pharma Data
JUNE 7, 2023
a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
Drug Discovery World
JULY 15, 2024
Additionally, Ariceum Therapeutics’ Head of Translational Biology & Non-Clinical Pharmacology, Anika Jäkel, also described the conference agenda as “truly diverse,” which covered “many forms of therapeutic approaches, with some revelatory findings about new biomarkers that could lead to a new generation of personalised therapies.”
Expert insights. Personalized for you.
52 
Let's personalize your content